Cases & Deals

  • Home
  • Practices
  • Celgene files patent infringement charges against Actavis and Abrika over generic versions of ADHD drug Focalin XR®

Share

Celgene files patent infringement charges against Actavis and Abrika over generic versions of ADHD drug Focalin XR®

October 2007

Client(s) Celgene Corporation

Jones Day represented Celgene Corporation in a Hatch-Waxman patent infringement action involving Celgene's branded ADHD drug Focalin XR®. This matter concluded through a mutually agreeable settlement.

Celgene Corporation, et al. v. Actavis South Atlantic, LLC and Abrika Pharmaceuticals, Inc., Case No. 3-07-cv-05367 (D.N.J.) (Judge Wolfson)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.